Leading the Way in Life Science Technologies

GEN Exclusives

More »

The Lists

More »
Aug 12, 2013

The 20 Top Paid Women Executives in Biopharma

Who are the highest-paid females in the industry this year?

The 20 Top Paid Women Executives in Biopharma

See how well these 20 sisters are doin’ it for themselves. [© stefa_neve - Fotolia.com]

  • Following is a list of 20 women executives holding top positions with biotech or pharmaceutical companies for at least part of 2012, ranked by their “total compensation” last year. Total compensation goes beyond salary to include bonuses, stock awards, stock option awards, nonequity incentive plan compensation, and all other sources of compensation. For each woman ranked, the list offers 2012 and 2011 compensation, the percentage change between the amounts, and their position (if ranked) on last year’s top paid women in biopharma list, published by GEN on July 31, 2012.

    The salaries for the women executives ranked on this list trail significantly the pay levels seen in the CEO list, but only in part because this list includes many women in executive positions below CEO. The four women CEOs on this list—Heather Bresch of Mylan, Martine Rothblatt of United Therapeutics, Michelle Dipp, M.D., Ph.D., of OvaScience, and Robin Smith of NeoStem—all received less in compensation than every one of the top 15 CEOs appearing on GEN’s list of top biopharma CEOs ranked by pay.

    As with GEN’s recent CEO compensation list, this list shows the continuing leveling of the industry between traditional “big” pharma and biotech. Six of the top 10 women executives on this list work at pharmas; the rest, at biotechs. However, positions 11–20 on the list were filled entirely by biotech executives, which reflects another reality: that pharmas are still transitioning from years of their executive ranks being dominated by men.

    Another result of note: Of the 20 women on this list, 10 held positions at the executive or senior vice presidential level, and seven of those had responsibilities that included that of general counsel. One woman was a chief medical officer, and another a chief commercial officer.

  • #20. Mary Sontrop

    Company: CSL

    Title: EVP, Operations

    2012 Compensation: $1,414,920 (A$ 1,589,344)1

    2011 Compensation: $1,190,883 (A$ 1,337,883)1

    % Change: 18.8%

  • #19. Robin Smith

    Company: NeoStem

    Title: CEO

    2012 Compensation: $1,643,403

    2011 Compensation: $3,647,772

    % Change: -54.9%

  • #18. Maria E. Cantor

    Company: Ariad Pharmaceuticals

    Title: SVP, Corporate Affairs

    2012 Compensation: $1,697,5602

    2011 Compensation: N/A2

    % Change: N/A2

  • #17. Kathryn L. Biberstein

    Company: Alkermes

    Title: SVP, General Counsel, Secretary and Chief Compliance Officer

    Year Ending March 31, 2013 Compensation: $2,113,308

    Year Ending March 31, 2012 Compensation: $1,949,493

    % Change: 8.4%

  • #16. Anne Marie Cook

    Company: Aegerion Pharmaceuticals

    Title: SVP, General Counsel and Secretary

    2012 Compensation: $2,258,032

    2011 Compensation: N/A3

    % Change: N/A3

  • #15. Suzanne M. Shema, J.D.

    Company: Onyx Pharmaceuticals

    Title: EVP, General Counsel and Corporate Secretary

    2012 Compensation: $2,724,077

    2011 Compensation: $1,882,070

    % Change: 44.7%

  • #14. Cheryl L. Cohen

    Company: Medivation

    Title: Chief Commercial Officer

    2012 Compensation: $2,880,757

    2011 Compensation: $3,554,5194

    % Change: -19.0%

  • #13. Lynn Seely, M.D.

    Company: Medivation

    Title: CMO

    2012 Compensation: $3,058,474

    2011 Compensation: $2,579,028

    % Change: 18.6%

  • #12. Michelle Dipp, M.D., Ph.D.

    Company: OvaScience

    Title: CEO

    2012 Compensation: $3,442,618

    2011 Compensation: $1,4205

    % Change: N/A5

  • #11. Jane Wasman, J.D.

    Company: Acorda Therapeutics

    Title: President, International General Counsel and Corporate Secretary

    2012 Compensation: $3,448,808

    2011 Compensation: $1,645,473

    % Change: 109.6%

    Do you think the women on our list of the 20 top paid women executives in biopharma are underpaid?

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »